Early visual and morphologic changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
OBJECTIVE
To evaluate the early functional and morphologic changes in patients with chronic central serous chorioretinopathy (CSC) after half-fluence photodynamic therapy (PDT) and to compare with fellow eyes.


METHODS
This prospective study included 32 symptomatic and 28 fellow eyes of 32 patients with chronic CSC. Indocyanine green angiography-guided half-fluence PDT (25 J/cm(2)) was performed. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), and subfoveal choroidal thickness (SFCT) were evaluated at baseline and at days 1, 3, 7, 30, and 60 after PDT.


RESULTS
The mean age was 48.1±7.9 years. Baseline BCVA [logarithm of the minimum angle of resolution (logMAR)] improved from 0.56±0.23 to 0.54±0.24, 0.45±0.25, 0.38±0.23, 0.36±0.23, and 0.35±0.21 at days 1, 3, 7, 30, and 60. (P=0.91, P=0.004, P=0.002, P=0.001, and P<0.001, respectively). Baseline CFT decreased from 315±131 to 312±136, 305±136, 235±106, 174±44, and 165±36 μm at days 1, 3, 7, 30, and 60 (P=0.41, P=0.33, P=0.004, P<0.001, and P<0.001, respectively). Baseline SFCT in the symptomatic eyes was significantly greater compared with the fellow eyes (P=0.002) and changed from 517±98 to 546±109, 528±110, 495±119, 462±124, and 457±123 μm at days 1, 3, 7, 30, and 60 (P=0.02, P=0.42, P=0.07, P=0.004, P=0.003, respectively).


CONCLUSIONS
The SFCT in the symptomatic eyes was greater in the fellow eyes at baseline. Functional and morphological chorioretinal changes started in very early period of treatment. Half-fluence PDT for chronic CSC resulted in thinner CFT and SFCT, and also showed a significant improvement in visual acuity.
1 Department of Retina, Beyoglu Eye Training and Research Hospital , Istanbul, Turkey .
Zeynep
Z
Alkin
Abdullah
A
Ozkaya
Alper
A
Agca
Ahmet Taylan
AT
Yazici
Ahmet
A
Demirok
D000328:Adult; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000473:pathology*; D002908:Chronic Disease / Q000188:drug therapy*; D004396:Coloring Agents / Q000008:administration & dosage*; D005260:Female; D005451:Fluorescein Angiography / Q000379:methods; D005584:Fovea Centralis / Q000187:drug effects / Q000473:pathology; D006801:Humans; D007208:Indocyanine Green / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D011446:Prospective Studies; D014792:Visual Acuity / Q000187:drug effects
D004396:Coloring Agents; D017319:Photosensitizing Agents; D007208:Indocyanine Green